EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells by Laurenzana, A et al.
EBioMedicine 39 (2019) 194–206
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomedic ine.comEGFR/uPAR interaction as druggable target to overcome vemurafenib
acquired resistance in melanoma cellsAnna Laurenzana a,⁎, Francesca Margheri a, Alessio Biagioni a, Anastasia Chillà a, Nicola Pimpinelli b,
Jessica Ruzzolini a, Silvia Peppicelli a, Elena Andreucci a, Lido Calorini a, Simona Serratì c,
Mario Del Rosso a,⁎, Gabriella Fibbi a
a Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale G.B. Morgagni, 50, 50134 Florence, Italy
b Dermatology Unit, Department of Surgery and Translational Medicine, University of Florence, Viale Michelangiolo, 41, 50125 Florence, Italy
c Nanotecnology Laboratory, National Cancer Research Centre, IRCCS “Giovanni Paolo II”, Viale Orazio Flacco, 65, 70124 Bari, Italy⁎ Corresponding authors.
E-mail addresses: anna.laurenzana@unifi.it (A. Lauren
(M. Del Rosso).
https://doi.org/10.1016/j.ebiom.2018.12.024
2352-3964/© 2018 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 4 July 2018
Received in revised form 12 December 2018
Accepted 12 December 2018
Available online 2 January 2019Background: BRAF inhibitor (BRAF-I) therapy for melanoma patients harboring the V600E mutation is initially
highly effective, but almost all patients relapse within a few months. Understanding the molecular mechanisms
behind BRAF-I responsiveness and acquired resistance is therefore an important issue. Here we assessed the role
of urokinase type plasminogen activator receptor (uPAR) as a potentially valuable biomarker in the acquisition of
BRAF-I resistance in V600E mutant melanoma cells.
Methods:We examined uPAR and EGFR levels by real time PCR and western blot analysis. uPAR loss of function
was realized by knocking down uPAR by RNAi or usingM25, a peptide that uncouples uPAR-integrin interaction.
We investigated uPAR-β1integrin-EGFR association by co-immunoprecipitation and confocal immuno-
fluorescence analysis. Acquired resistance to BRAF-I was generated by chronic exposure of cells to vemurafenib.
Findings:We proved that uPAR knockdown in combination with vemurafenib inhibits melanoma cell prolifera-
tion to greater extent than either treatment alone causing a decrease in AKT and ERK1/2 phosphorylation.
Conversely, we demonstrated that uPAR enforced over-expression results in reduced sensitivity to BRAF inhibi-
tion. Moreover, by targeting uPAR and EGFR interaction with an integrin antagonist peptide we restored
vemurafenib responsiveness in melanoma resistant cells. Furthermore, we found significant detectable uPAR
and EGFR levels in tumor biopsies of 4 relapsed patients.
Interpretation:We disclosed an unpredicted mechanism of reduced sensitiveness to BRAF inhibition, driven by
elevated levels of uPAR and identified a potential therapeutic strategy to overcome acquired resistance.
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EGFR1. Introduction
Metastatic melanomas are the deadliest form of skin cancer and
have the highestmutational loads of all cancers [1]. Until recently, effec-
tive treatments for surgically unresectable or metastatic melanoma
were lacking. At the most, cytotoxic chemotherapy such as dacarbazine
or immunotherapies with interleukin-2 (IL-2) for instance, yield
response rate of approximately 10%. Even though these responses may
be extremely durable, neither aforementioned treatments results in
improved overall survival (OS) [2–4].lrosso@unifi.it
an open access article underEncouraging perspectives for patients with advancedmelanoma sig-
nificantly arose with the identification of specific BRAF and MEK inhib-
itors and immunemodulating antibodies [5] as effective therapies. BRAF
is a serine–threonine-specific protein kinase, belonging to the RAF fam-
ily (RAF1, ARAF, and BRAF) of kinases, that act downstream of RAS and
upstreamofMEK in theMAPK signaling pathways,mediating cell prolif-
eration in response to several growth signals under normal signaling
conditions. Dysregulation of the MAPK pathway is a key feature in the
majority of melanomas. Indeed, about 28% of melanomas contain
activating mutations in NRAS [6,7], whereas approximately 52% of all
melanomas contain a mutation in the BRAF gene, most commonly
resulting in substitution of valine for glutamic acid at position 600
(V600E) [8,9]. The BRAFV600E substitution leads to constitutive activa-
tion of this kinase and, consequently, of constitutive ERK signaling. Inhi-
bition of the BRAF (V600E) oncoprotein by the small-molecule drugthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before the study
Oncogenic mutations in the BRAF gene, that cause the protein to
become overactive, are present in about 7% of human cancers
and in about 50% of advanced (unresectable or metastatic) mela-
nomas. BRAFmutation status is the only biomarker that predicts a
therapeutic response in advanced melanoma, making possible to
treat melanoma patients with inhibitors of mutated BRAF (BRAF-
I, such as vemurafenib). Unfortunately, patients relapsewithin 6–-
8months from the beginning of therapy due to the development of
different mechanisms of acquired tumor drug resistance. The ca-
pability to by-pass the inhibitor effect can be achieved through dif-
ferent mechanisms: emergence of BRAF alternative gene
expression variants, mutations in the mitogen cascade (MAPK
pathway), or activation of alternative cell survival signals (PI3k/
AKT/mTOR pathway).
Added value of this study
In the present studywe showed that among the several molecular
effectors involved in BRAF resistance to vemurafenib, the uroki-
nase plasminogen activator receptor (uPAR) plays a crucial role.
Indeed, we demonstrated that cells with different uPAR expres-
sion levels display variable sensitivity to the BRAF-I. More impor-
tantly, we proved that resistance to Vemurafenib depends on
uPAR-EGFR interaction, and identified a potential therapeutic
strategy to inhibit this interaction by using a small peptide able
to dissociate uPAR and EGFR. Such dissociation inhibits the
resistance-associated PI3k/AKT/mTOR pathway and leaves the
MAPK pathway, sensitive to vemurafenib, as the only signaling
pathway.
Implication of all the available evidence
Our data suggest that uPARmay be a useful biomarker to identify
patients with BRAF-mutant melanomawho will (low uPAR levels)
or will not (high uPAR levels) respond to BRAF inhibitors. Indeeed,
the evaluation of uPARexpression levels onV600Emutant patient
might improve drug combination design that will lead to more po-
tent, durable personalized therapy. Last, treatment with the small
peptide used in this work, may have the chance to restore
vemurafenib sensitivity in relapsed patients.
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treatment of tumors harboring the BRAF (V600E) mutation [10],
especially in melanoma patients. However emergence of acquired
drug resistance based on the recovery of constitutive reactivation of
MAPK signaling by secondary mutations in NRAS and MEK [11,12] or
on activation of alternative signaling pathways by relevant growth fac-
tor receptors [13,14], or on the emergence of BRAF alternative splicing
isoforms [15], limits clinical benefit. Thus, effective therapies that ad-
dress both de novo and acquired resistance to BRAF andMEK inhibitors
remain a subject of active research. Understanding themechanisms un-
derlying resistance to vemurafenib, its analogs, or dabrafenib, provides
an important basis for developing rational strategies to treat patients
with BRAFV600- mutated melanoma who do not respond to BRAF in-
hibitors, or to treat patients who progress on these therapies.
Among the several molecular effectors involved in drug resistance
and, in particular, in BRAF resistance to vemurafenib, the urokinase
plasminogen activator receptor (uPAR) might play a crucial role in
view of its involvement in intracellular signaling, activation of latentgrowth factors, extracellular matrix degradation and tumor neo-
angiogenesis [16–19]. Several malignant tumors show a positive corre-
lation between uPAR levels and a more aggressive phenotype together
with a poor prognosis. uPAR is able to regulatemultiple signaling events
stimulating several growth factor receptors independently of the pres-
ence of the specific cognate ligands [20]. Indeed, α5β1, α3β1, αvβ3
and αvβ5 integrins through their alpha chain interact with uPAR in a
RGD-independent fashion and with receptor tyrosine kinases (RTK)
such as EGFR [21–23], PDGFR, G-protein coupled receptors (GPCR)
and MET [24–26]. uPAR-associated growth factor receptors signal
through a ligand-independent uPAR/integrin fashion, activating the
main transduction pathway, namely the PI3K/AKT/mTOR, that is also
activated at the onset of vemurafenib resistance in tumors harboring
the BRAF V600E mutation [27].
In this studywe provide for thefirst time in vitro evidence that uPAR
levels in BRAF mutant melanoma cells are a key element of response to
BRAF inhibition. Indeed, we demonstrated that cells with different uPAR
expression levels showvariable sensitivity toVemurafenib. uPAR silenc-
ing through RNA interference in A375-M6 metastatic melanoma cells
expressing high uPAR levels, restored sensitivity to vemurafenib and
induced a more pronounced down-regulation of ERK signaling. Con-
versely, we proved that uPAR over-expression in cells with moderate
uPAR levels results in reduced sensitivity to BRAF inhibition. In addition
we cultured BRAF-mutant A375M6 cells in the presence of Vemurafenib
until the emergence of resistant derivative and describe a promising
combinatorial strategy to address acquired resistance to monotherapy.
Lastly, we retrospectively assessed the impact of EGFR or uPAR ex-
pression levels on clinical outcomes in 6 patients with metastatic mela-
noma treated with vemurafenib. We found significant detectable uPAR
and EGFR levels in 4 relapsed patients and two of them exhibited very
high levels of mRNA relative to both markers. Our data suggest that
uPAR may be a useful biomarker to identify patients with BRAF-
mutant melanoma who will or will not respond to BRAF inhibitors
(BRAF-I).
2. Materials and methods
2.1. Cell lines and culture conditions
The human melanoma cell lines CRL-1619 A375 (MITF wild type,
BRAF V600E, NRAS wild type)were obtained from American Type Cul-
ture Collection (Manassas, VA) and were grown in Dulbecco's Modified
Eagle Medium high glucose (DMEM 4500, EuroClone, MI, Italy)
containing 2 mM glutamine and supplemented with 10% FBS
(Euroclone,Milano, Italy). A375-M6melanoma cells (M6)were isolated
in our laboratory from lung metastasis of SCID bg/bg mice i.v. injected
with A375 cells. A375, and M6 were independently validated by STR
profiling by the DNA diagnostic center BMRGenomics (Padova, Italy).
Cells were amplified, stocked, and once thawed were kept in culture
for a maximum of 4 months.
In some experiments we used also the human melanoma cell lines
WM266-4 (from ATCC), M14, M20, Mewo, W1361A. Melanoma cells
were cultivated in DMEM supplemented with 10% fetal bovine serum
(FBS) at 37 °C in humidified atmosphere containing 90% air and 10%
CO2. Cells were harvested from subconfluent cultures by incubation
with a trypsin-EDTA solution (EuroClone, MI, Italy), and propagated
every four days. Viability of the cells was determined by trypan blue ex-
clusion test. Cultures were periodically monitored for mycoplasma con-
tamination using Chen's fluorochrome test.
2.2. Generation of vemurafenib-resistant population
M6 cells were plated at low density (5 × 104) on 10 cm dishes and
24 h later they were treated with 2 μM vemurafenib. Once the cells
gained the ability to grow in the presence of vemurafenib (PLX4032,
MedChemtronica AB, Stockholm, Sweden), which happened about
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and analyzed by molecular and cellular assays.
2.3. Cell treatments with M25, MEK1/2, ERK1/2 specific inhibitors
Inhibition of uPAR-integrin interaction was obtained with the M25
peptide, previously identified in a phage display library, able to uncou-
ple uPAR from integrinα-chain. The peptidewas produced in collabora-
tion with the Peptide Facility at Biotechnology Center, University of
Padova (CRIBI). In the β-propeller model of α-chain folding, the se-
quence of this peptide (STYHHLSLGYMYTLN) spans an exposed loop
on the ligand-binding surface of α-chain, thus impairing integrin α
chain-uPAR interaction. In cell culture M25 water solution was used
at 50 μM at 37 °C. MEK1/2 inhibition was achieved with 1 μM CI-1040
(Cayman Chemical) while ERK1/2 inhibition was obtained with 1 μM
SCH772984 (Cayman Chemical).
2.4. Cell viability determination
The viability of A375 and A375-M6 cells was determined by trypan
blue staining. Cells (1.5× 105)were seeded in 6-well plates and allowed
to attach overnight. On the next day cells were treated with
Vemurafenib at the indicated concentrations. 96 h later 20 μL of cell sus-
pension were aseptically transferred to a 1.5 mL clear Eppendorf tube
and incubated for 3 min at room temperature with an equal volume
of 0.4% (w/v) trypan blue solution prepared in 0.81% NaCl and 0.06%
(w/v) dibasic potassium phosphate. Viable and nonviable cells (trypan
blue positive) were counted separately using a dual-chamber hemocy-
tometer and a light microscope. The means of three independent cell
counts were pooled for analysis.
2.5. Clonogenic assay
Cells were seeded (8 × 102) in six well plates and treated with vehi-
cle (DMSO) or different doses of vemurafenib. After 10 days, cells were
fixed and stained with MayGrunwald-Giemsa. The number of colonies
were counted and reported in graphs.
2.6. Tumor spheroid formation
Tumor cell monolayers were washed with PBS and then harvested
using Trypsin, collected and centrifuged at 500 x g for 5 min. 500
cells/well were seeded dispensing 500 μL per well into a 24-well flat-
bottomed plate precoated with 1.5% Agar. The plate was then trans-
ferred to an incubator (37 °C, 5% CO2, 95% humidity). Four days later,
after the tumor spheroids formation was visually confirmed, the 3D
tumor colonies were treated with vemurafenib, M25 peptide or combi-
nation (vemurafenib+M25) for one additional week. Images were col-
lected and analyzed by ImageJ software (developed byWayne Rasband,
National Institutes of Health, Bethesda, MD; available at http://rsbweb.
nih.gov/ij/index.html). Estimated area was measured after drawing a
yellow circle around the selected spheroid.
2.7. Spheroid-based migration assay
500 cells were resuspended in 150 μL ofmedia and plated on an aga-
rose base (PBS plus 1.5% agarose) in 96well plate. Four days later tumor
spheroids formation was visually confirmed, cells were treated with ei-
ther DMSO or 2uM vemurafenib or M25 or combination and 50 ul of
Matrigel (BD Biosciences) (125 μg/mL) were dispensed into the inner
wells. Each experimental condition was plated in triplicate. After
3 days, images were collected and analyzed by ImageJ software. The in-
vasive ability was evaluated by measuring the total area outside the
spheroid. Invasive area are first defined using the software draw tool,
after which comparative values are generated as pixel measurements.2.8. RNA extraction, semiquantitative and quantitative PCR
Total RNA was prepared using Tri Reagent (Sigma-Aldrich, Saint
Louis, Missouri, USA), agarose gelchecked for integrity, and reverse
transcribed with cDNA sintesys kit (BioRad, Milano, Italy) according to
manufacturer's instructions. Selected genes were evaluated by qualita-
tive PCR using Blue Platinum PCR Super Mix (Life Technologies,
Monza, Italy) or Real-Time PCR using SsoAdvanced Universal Green
Mix (BioRad, Milano, Italy) with 7500 Fast Real Time PCR System
(Applied Biosystems, Waltham, Massachusetts, USA). For Real Time
PCR, fold change was determined by the comparative Ct method using
β2-Microglobulin as the normalization gene. Amplification was per-
formed with the default PCR setting: 40 cycles of 95 °C for 10 s and of
60 °C for 30 s using SYBR Green–based detection. Primer sequences
(IDT, TemaRicerca, Bologna, Italy) were as follows:
18S-rRNA: sense, 5′-CCAGTAAGTGCGGGTCATAAG-3′; antisense, 5′-
GCCTCACATAA-CCATCCAATC-3′.
uPAR: sense, 5′-GCCCAATCCTGGAGCTTGA-3; antisense, 5′- TCCCCT
TGCAGCTGTA-ACACT-3′.
EGFR sense 5′-GGTGCGAATGACAGTAGCATTATGA-3′; EGFR anti-
sense, 5′-AAAGGTGGGCTCCTAACT-AGCTGAA-3′.
2.9. Western blot analysis
Harvested cells were resuspended in 20 mM RIPA buffer (pH 7.4)
(Merk Millipore, Vimodrone, MI, Italy) containing a cocktail of protein-
ase inhibitors (Calbiochem,Merck, Darmstadt, Germany) and treated by
sonication 19(Microson XL-2000, Minisonix, Farmingdale, NY, USA).
Aliquots of supernatants containing equal amounts of protein
(30 μg) in Laemmli buffer were separated on Bolt® Bis-Tris Plus gels
4–12% precast polyacrylamide gels (Life Technologies, Monza, Italy).
Fractionated proteins were transferred from the gel to a PVDF nitrocel-
lulose membrane using iBlot 2 system (Life Technologies, Monza, Italy).
Blots were stained with Ponceau red to ensure equal loading and com-
plete transfer of proteins, then they were blocked for 1 h, at room tem-
perature, with 5% milk in PBS 0.1% tween solution. Subsequently, the
membrane were probed at 4 °C overnight with the following primary
antibodies: rabbit anti-pAKT (1:1000, Cell signaling Technology, Cat#
9271), rabbit anti AKT (1:1000, Cell signaling Technology, Cat# 4691),
rabbit anti-pERK1/2 (1:1000, Cell signaling Technology, Cat# 9101),
mouse anti-ERK1/2 (1:1000, St Cruz Biotechnology, Cat# sc-514,302),
rabbit anti-pmTOR (Ser2448) (1:1000 Cell signaling Technology, Cat#
2971) and rabbit anti-mTOR (1:1000 Abcam Cat# ab2732); rabbit
anti-uPAR (1:500 FL 290, Santa Cruz Biotechnology, Cat# sc-10,815);
rabbit anti-EGFR (1:500, Santa Cruz Biotechnology, Cat# sc-03), rabbit
GAPDH antibody (1:1000, Cell signaling Technology, Cat# 2118) or
mouse anti-α-tubulin monoclonal antibody (1:2000, Sigma, Cat
#T6199) were used to assess equal amount of protein loaded in each
lane. Anti-Rabbit IgG (whole molecule)–Peroxidase antibody (Sigma,
Cat#A0545) or anti-Mouse IgG (whole molecule)–Peroxidase antibody
(Sigma, Cat#A9044)have been used as secondary antibodies; the ECL
procedure was employed for development.
2.10. uPAR gene silencing and uPAR gene overexpression
Targeting and not-targeting siRNAs were obtained from
Dharmacon (Carlo Erba Reagents, Milan, Italy). Specific silencing of
uPAR and EGFR genes were performed by transfection of M6 and
A375 with small-interfering-RNA (siGENOME SMARTpool, according
to themanufactures's instruction). To favour cell internalization siRNAs
were incorporated into cationic liposomes, utilizing DharmaFECT trans-
fection reagent. Cells were incubatedwith transfectionmix (24–48 h for
mRNA analysis and 48 h for protein and phenotypic analysis, respec-
tively). A375 and M6 were subjected to uPAR overexpression tran-
siently transfecting these cell lines with the pQ2 plasmid which was
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control of a strong promoter.
2.11. Cell cycle analysis
Cell cycle distribution was analyzed by the DNA content using
propidium iodide (PI) staining method. Cells were centrifugate and
stained with a mixture of 50 μg/ml PI (Sigma-Aldrich, St. Louis, Mis-
souri), 0.1% trisodium citrate and 0.1% NP40 (or triton x-100) in the
dark at 4 °C for 30 min. The stained cells were analyzed by flow cytom-
etry (BD-FACS Canto) using red propidium-DNA fluorescence.
2.12. Confocal microscopy analysis
Cells were grown on glass coverslips, washed twicewith 1ml of PBS,
fixed for 20 min in 3.7% paraformaldehyde in PBS and permeabilized
with 0.1% Triton X-100 in PBS for 5 min. The cells were incubated in
blocking buffer (3% BSA and 0.1% Triton X-100 in PBS) for 1 h at room
temperature and then stained with the appropriate antibody overnight
at 4 °C: mouse anti-uPAR (1:200, Thermo Fisher Scientific, Cat#Mon
R-4-02), rabbit anti-Integrin α5β1(Biocomapare, Cat# NBP2-52680)
and goat anti-EGFR (Santa Cruz Biotechnology, Cat# sc-31155). Succes-
sively, the cells were incubated at room temperature for 1 h with the
specific secondary antibody: CY3-conjugated anti-mouse IgG (1:800;
Sigma-Aldrich, Cat# C2181), FITC-conjugated anti-rabbit IgG (1:800;
Sigma-Aldrich, Cat# F-4151) and Anti-Goat IgG (whole molecule)-
FITC (1:800; Sigma-Aldrich, Cat# F7367). Nuclei were stained with the
fluorescent Hoechst 33342 dye (DAPI) (10 μg/ml) (Invitrogen) for
15min at RT. The coverslips containing the labelled cells weremounted
with an anti-fade mounting medium (Biomeda, Foster City, CA) and
observed under a Bio-RadMRC 1024 ES Confocal Laser ScanningMicro-
scope (Bio-Rad, Hercules, CA) equipped with a 15 mW Krypton/Argon
laser source for fluorescence measurements. The cells were examined
with a Nikon Plan Apo X60-oil immersion objective using an excitation
wavelength appropriate for Alexa 488 (495 nm). Series of optical sec-
tions (XY: 512 × 512 pixels) were then taken through the depth of
the cells with a thickness of 1 μmat intervals of 0.8 μm (Z step). A single
composite image was obtained by superimposition of twenty optical
sections for each sample observed. The collected images were analyzed
by ImageJ software.
2.13. Immunoprecipitation and western blot
Protein concentration was determined using Bradford's method and
500 μg of total proteins were incubated with mouse monoclonal uPAR
antibody (Thermo Fisher Scientific, Cat#MON R-5-02) or with non-
specific IgG (Mouse IgG isotype control, Thermo Fisher Scientific, Cat#
10400C) used as negative control with gentle rocking for 3 h at room
temperature followed by incubation with dynabeads protein G
(Novex, Life Technologies,Waltham,MAUSA) overnight at 4 °C, accord-
ing to the manufacturer's instructions.The day after the beads were
washed six times with lysis buffer, boiled for 5 min in SDS-loading
buffer and subjected to SDS–PAGE and western blot. Nitrocellulose
membranes were blocked and then probed overnight at 4 °C, with the
polyclonal anti-uPAR (1:500 FL 290, Santa Cruz Biotechnology, Cat#
sc-10,815); the anti-α5β1 integrin (1:500, Millipore, Cat# MAB2514)
and the polyclonal EGFR (rabbit, Santa Cruz Biotechnology, Cat# sc-
03). Then, the membranes were rinsed, incubated with peroxidase-
conjugated anti-rabbit immunoglobulin G (1 h, room temperature).
After extensive washes, the reaction was revealed using the detection
system from GE Healthcare (Milano, Italy the Super Signal West).
2.14. Clinical samples
Clinical samples were collected from 6 melanoma patients at the
Plastic and Reconstructive Surgery Unit, Regional Melanoma ReferralCenter andMelanoma& Skin Cancer Unit, Florence, Italy, after obtaining
informed written consent. The study was conducted according to the
1964 Helsinki declaration and Local Institutional Ethics Committee ap-
proval. The main characteristics of the patients, their clinical responses
according to the classical RECIST1.1 [28] evaluation criteria, and the
histological variables such as Breslow thickness (mm), melanoma sub-
types, stage, presence of ulceration, mitotic rate (n./mm2) are reported
in Fig. 6.
2.15. Formalin-fixed paraffin-embedded (FFPE) RNA extraction sample and
quantitative RT-PCR (qRT-PCR)
Eight to ten 10 μm-thick sections were cut from each block of FFPE
tissue, transferred to 1.5-ml sterile tubes, and processed using the
PureLink FFPE Total RNA Isolation Kit (Invitrogen, by Thermofisher)
according to the manufacturer's protocol. Briefly, RNA was extracted
by spin column purification according to similar basic principles:
deparaffinization, followed by cell disruption with heated proteinase
K, which is capable of efficiently degrading proteins that were cova-
lently cross-linked with each other and RNA. Proteinase K incubation
at high temperature (60 to 70 °C) also removes part of themethylol ad-
ditions induced by formalin fixation [29]. After proteinase K incubation,
RNA was isolated by alcohol precipitation in a spin column purification
step and then was stored at−80 °C. Total RNA 260/280 OD ratios were
consistently between 1.7 and 1.85, indicating high sample purity.
500 ng RNA was reverse-transcribed using Thermo Scientific Max-
ima H Minus cDNA Synthesis Master Mix with dsDNase (Invitrogen,
by Thermofisher) according to manufacturer's instructions. cDNA was
amplified (50 °C, 2 min, 95 °C, 10 min, 95 °C, 15 s, 60 °C, 1 min, 50×),
and ΔCt was determined using TaqMan Gene Expression duplex
assay specific for PLAUR (FAM-MGB, Minor Groove binder, Applied
Biosystem) and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(VIC-MGB primer limited), employed as reference transcript, on the
7500 Applied Biosystem Real-Time PCR System. Similar protocols
were obtained to quantify uPAR and EGFR expression levels using a
SYBR Green–based detection method (Applied Biosystems).
2.16. Statistical analysis
Data were analyzed using GraphPad Prism 6 and expressed as mean
±SD. The statistical tests used are stated in the Figure legends. A p value
of b0.05 was considered significant.
3. Results
3.1. EGFR and uPAR levels in melanoma cells
Given the notion that EGFR levels determine the response to BRAF
inhibitor monotherapy [30] and taking in consideration the strong en-
gagement between EGFR and uPAR in melanoma cells [31],we com-
pared EGFR and uPAR protein levels in a panel of wild type and BRAF
(V600E) mutant melanoma cell lines (Fig. 1a). Melanoma cells indeed
express low or moderate levels of EGFR and uPAR: of the seven mela-
noma cell lines examined only three, namely W1361A (BRAF wt),
A375 e M6 (BRAF V600E), express much higher levels of EGFR and
uPAR (Fig. 1b) and constitutive activation of ERK occurred only in two
out of 7 cell lines. In order to establish a potential direct correlation be-
tween EGFR and uPAR levels, we ablated uPAR in M6 overexpressing
cells with specific siRNA smart pools (siPLAUR) for 48 h that efficiently
down regulated uPAR expression (Fig. 1c) while induced a slight in-
crease of EGFR expression (Fig. 1d) and protein levels (Fig. 1e) as
assessed by PCR and immunoblotting. Furthermore, the inverse experi-
ment of EGFR silencing did not result in any significant effect on uPAR
expression (Fig. 1e) and protein levels (Fig. 1f). As EGFR did not cause
any change in uPAR protein expression, we continued to investigate
the effect of uPAR overexpression in A375 cells on EGFR gene
Fig. 1.uPAR, EGFR expression level association inmelanoma cells. a. List ofmelanoma cell lines evaluated for uPAR, EGFR and pERK1/2 protein levels. b.Western blot analysis of EGFR, uPAR
and phosphorylation ERK1/2 levels with related densitometric quantification normalized to the internal control. Numbers on the right refer to molecular weights expressed in kDa. c, d.
Real time PCR analysis was performed in M6 cells transfected with specific uPAR or EGFR siRNAs and no targeting siRNA as Control, to evaluate the expression levels of uPAR and EGFR.
Results of three independent experiments performed in triplicates are expressed as fold changeaccording to 2−ΔΔCT method, using 18S as calibrator. Statistical analysis was performed
using unpaired Student's t-test, Error bars: mean ± SD; *p b .05 compared to Control. e, f. Cellular extracts of M6 before and after gene silencing were immunoblotted with antibodies
against uPAR and EGFR. GAPDH was included as a loading control. Relative protein levels of uPAR and EGFR were quantified by densitometry and reported as values normalized to the
GAPDH. Statistical analysis was performed using unpaired Student's t-test, Error bars: mean± SD; *p b .05 compared to Control. g. Cellular extracts of A375 before and after enforced ex-
pressionwith pQ2-uPARplasmidwere analyzedwith antibodies against uPAR and EGFR. GAPDHused as a loading control. Densitometric analysis of the levels of the sameproteins relative
to GAPDH expression. Error bars indicate mean± SD; n= 3 experiments; Statistical analysiswas performed using unpaired Student's t-test, Error bars: mean± SD; *p b .05 compared to
Mock Control.
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low endogenous expression levels did notmodify EGFR levels compared
with the same cells transfected with the empty vector (Fig. 1g), thereby
concluding that nomono-directional ormutual regulation of expression
is appreciable between uPAR and EGFR in melanoma cells.
3.2. Correlation between EGFR levels and uPAR levels and response to BRAF
inhibition in melanoma
Given the observation that uPAR and EGFR are differentially
expressed in A375 cell line and in its highly metastatic derivative M6,
(Fig. 2a, Fig. 2b), we tested the two cell lines for their response to
Vemurafenib in short term and long term cultures (Fig. 2c, Fig. S1 and
2d). For the short term assay, cells were treatedwith increasing concen-
trations of vemurafenib for 96 h, and cell viability was determined by
Trypan blue assay, while for the long term assay cells were grown in
the absence or presence of vemurafenib at the indicated concentrations
for 10 days. For each cell line, all dishes were fixed at the same time,
stained and photographed. As reported in Fig. 2c, in both cell lines the
treatment promoted at each dose a flat and elongated morphology
and reduced cell proliferation. However, M6 cells seemed to be less re-
sponsive than A375 cells to vemurafenib-mediated cytostasis as shown
by the fact that a similar growth inhibition in the two cell lines was ob-
tained only by treating M6 cells with a dosage five times higher (5 μM)
in the short term assay and 10 times higher in the long term assays than
that employed for A375 cells (Fig. 2d). Since the major molecular effect
of vemurafenib is inhibition of the MAPK signaling pathway, with a
strong reduction of ERK phosphorylation, leading to downstream sup-
pression of cyclin D1 we confirmed its activity evaluating thephosphorylation levels of ERK (Fig. 2e), the expression (Fig. 2f) and pro-
tein levels of Cyclin D1 (Fig. 2g) byWestern blot and real timePCR inM6
and A375 cells after 48 h treatment. As shown in figure, both cell lines
responded to treatment with 0.5 μM vemurafenib that dramatically re-
duced the phosphorylation of ERK1/2, and expression and protein levels
of Cyclin D1.
Notably, these results showed that the sensitivity of melanoma
along with both short-term (Fig. 2c) and long-term (Fig. 2d) prolifera-
tion assays and western blot analysis mirrors the expression levels
of EGFR and uPAR (Fig. 2b), withA375 being more sensitive to
Vemurafenib than M6 cells.
3.3. uPAR overexpression prevents the sensitivity of melanoma cells to
vemurafenib
To elucidate the role of uPAR in vemurafenib responsiveness, sepa-
rate ablation and overexpression experimentswere performed using ei-
ther siRNA-PLAUR or pQ2-DNAuPAR in M6 and A375 cells respectively.
We depleted uPAR by transfecting siRNA-PLAUR into M6 cells and then
subjected the cells to treatment with increasing concentrations of
Vemurafenib. We found that siRNA-mediated depletion of uPAR
strongly reduced the colony number compared to control siRNA
(siCTRL) treated cells (Fig. 3a) and powerfully enhanced the sensitivity
to vemurafenib. Indeed, the number of total colonies decreased in a dose
dependent manner and even the lowest vemurafenib dose significantly
diminished colony size and number. Moreover, long term proliferation
assay after uPAR silencing in A375 (Fig. S2 a, b) in presence of increasing
concentrations of vemurafenib substantiated the above results
confirming the direct involvement of uPAR in vemurafenib sensitivity.
Fig. 2.uPAR levels and responsiveness to BRAF inhibitor in A375 andM6melanoma cells. a. Schematic representation ofM6 generation. b. Immunoblotting for uPAR and EGFR in A375 and
M6,αTubulin used as internal control.c. M6 and A375were treated for 96 hwith increasing concentrations of vemurafenib. DMSO-treated cells were set as the control vehicle. Pictures of
treated cultures were taken with a phase-contrast microscopy (on the left), viable cells (trypan blu-negative) were counted with the aid of a Burker (on the right). Scale bar = 50 μm.
Statistical analysiswas performed using unpaired Student's t-test, Error bars: mean± SD; *p b .05 indicate significant differencefromDMSO. d. Clonogenic assay ofM6 and A375 cellsafter
a 10 d-treatment with the indicated doses of BRAF-I. Colonies were stained with May Grunwald and then counted. Statistical analysis was performed using student t-test. Representative
data of three independent experiments is shown (mean ± SD). Asterisks indicate significant differences (P b .05.) from DMSO-treated cells. e. Cells were treated with 0.5 μM or 1 μM
vemurafenib ERK1/2 phosphorylated and unphosphorylated levels were monitored by immunoblotting and quantified by densitometric analysis;αTubulin was also examined to ensure
equal loading of samples in each lane. f. mRNA levels of Cyclin D1were determined by qRT-PCR analysis. g.Western blot analysis of cyclin d1. The Student's t-test was used to analyze the
data. Error bars indicatemean±SD; n=3 experiments; *P b .05 indicates significant difference fromDMSO treated cells. All the experimentswere performed independently at least three
times.
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ERK1/2 and AKT phosphorylation compared to siCTRL-treated cells.
However, the addition of vemurafenib to uPAR depleted culture,
induced almost a complete disappearance of ERK phosphorylation,
and a significant decrease of AKT phosphorylation (Fig. 3b). Notably,
Vemurafenib treatment induced a substantial decrease of uPAR. Finally,
we tested whether ectopic expression of uPAR was sufficient to lower
vemurafenib sensitivity in A375 cells. We transduced EGFR/uPAR-low
expressing A375 with Q2-uPAR expression vector and exposed these
cells to treatment with increasing dose of Vemurafenib. Fig. 3c shows
that A375 uPAR overexpressing cells became less sensitive to
Vemurafenib as compared with the Mock control. Similar results were
observed after forced uPAR expression inM6 cells (Fig. S2 c, d). The rel-
ative MAPK and PI3K/AKT signaling reported in Fig. 3d alongwith uPAR
protein levels displays the less effectiveness of Vemurafenib on blocking
ERK phosphorylation in presence of higher uPAR expression that con-
comitantly induces an increase on AKT phosphorylation. Taken together
these results showed the uPAR might play an important role in the re-
sponse to therapy therapy for the subgroup of melanoma patients
with BRAF mutations.
Vemurafenib acquired resistance ofM6 cells leads to the reactivation
of the ERK pathway and confers fitness advantage in anchorage-
independent growth.
To verify whether uPAR-EGFR targeted therapy is an effective strat-
egy to overcome the acquired resistance to vemurafenib, we generated
vemurafenib-resistant M6 (M6R) cells selected by continuous drug ad-
ministration (Fig. 4a). First of all we analyzed the effects on cell cycle
distribution in M6 parental cells (M6P) and in the generated
vemurafenib resistant M6 after 24 h treatment with 1 μM or 2 μMvemurafenib. As expected, the G1 cell cycle block and reduction of
S-phase cells were pronounced and dose-dependent in the sensitive
parental cells (Fig. 4b) while the vemurafenib-resistant M6 cells were
insensitive to cell cycle arrest with N50% of the cell population in S
phase at all the vemurafenib concentrations tested (Fig. 4c). We then
evaluated the colony-forming ability of parental and vemurafenib-
resistant cells after long-term treatmentwith increasing concentrations
of the drug. As expected, we found that the vemurafenib-resistant cells
required higher doses of vemurafenib up to 10uM for a significant
growth inhibition (Fig. 4d). The reduced response to vemurafenib in
the resistant cells went along with an elevated constitutive activity of
theMAPK signalingpathway similar to that detected in parentalM6 cul-
tured in the absence of vemurafenib, whereas the level of pAKT and
pMTOR were not consistently changed. As predictable, treatment of
the wild type cells abrogated phosphorylation of ERK protein and led
to an increased phosphorylation of the PI3K pathway proteins which
is consistent with observations in literature [32,33]. Expression of
unphosphorylated proteins was not altered by treatment (Fig. 4e).
Since the anchorage-independent cell growth provides a useful tool
for modeling tumor response to treatment in vitro and most closely
mimics in vivo tumor growth, we measured the effect of vemurafenib
on the potential growth in soft agar of parental and resistant cells. Treat-
ment of M6 parental cells with a sole pulse of vemurafenib over 7 days
substantially reduced colony sizewhilemarginally affectedM6 resistant
cells which were maintained for 4 days before the treatment in
drug-free medium. In addition, resistant cells cultured in presence of
the drug exibited a greater growth in soft agar than cells withdrawn
from vemurafenib (Fig. 4f). Indeed, consistent with previous observa-
tion, resistant cells became addicted to the presence of the inhibitor
Fig. 3. uPAR overexpression prevents the sensitivity ofmelanoma cells to vemurafenib. a.M6 cells transfectedwith no targeting siRNA (siRNA Control) and a specific siRNA for uPAR. After
24 h the cells were seeded at the same density (800 cells/ml) and cultured in the presence of vemurafenib at indicated concentration for 10 days. The colonies were fixed, stained,
photographed and counted. The Student's t-test was used to analyze the data. Error bars indicate mean ± SD; n = 3 experiments; *p b .05 indicates significant difference from DMSO
treated cells b.M6 were transfected with PLAUR siRNA and negative control siRNA and incubated for 48 h in presence of 1 μM vemurafenib. Cells were harvested for immunoblotting
with the indicated antibodies. αTubulin was included as a loading control. Densitometric analysis of the expression of the same proteins normalized to the internal control is reported
on the right. Analysis of variance followed by Newman-Keuls post test was performed for comparing means of multiple groups. Error bars indicate mean ± SD; n = 3 experiments; *P
b .05 indicate significant difference of vemurafenib treated cell from DMSO treated control, and of combo treatment (vemurafenib + siRNA PLAUR) versus either DMSO or vemurafenib
treated cells. All the experiments were performed independently at least three times. c. A375 were transfected either with Mock or uPAR overexpressing plasmid pQ2-uPAR. After 24 h
were seeded at the same density (800 cells/ml) and cultured in the presence of vemurafenib at indicated concentrations for 10 days. The colonies were fixed, stained, photographed
and counted. Significance was assessed by Student's t-test. Error bars indicate mean ± SD; n = 3 experiments. *p b .05 indicates significant difference from DMSO treated cells. d.
A375Mock or uPAR transfected cells were harvested forWestern blot analysis for the indicated antibodies.αTubulin was included as a loading control. Densitometric analysis of the ex-
pression of the same proteins normalized to the internal control is reported on the right. Significancewas assessed by one-way ANOVA test followed byNewman-Keuls post test.Error bars
indicate mean± SD; Asterisks (*p b .05) indicate significant differences of vemurafenib treated cells, uPAR overexpressing cells or combo (vemurafenib+ pQ2-uPAR) fromMock treated
cells. All the experiments were performed independently at least three times.
200 A. Laurenzana et al. / EBioMedicine 39 (2019) 194–206resulting in greater growth in the presence of the inhibitor thanwithout
the drug.
3.4. Uncoupling uPAR and EGFR affects cellular proliferation, spheroid for-
mation, 3D cell invasion
It has been shown by Liu and coworkers [34] that highly malignant
tumor cells through overexpression of uPAR are able to exploit a tightly
regulated EGFR pathway to obtain a proliferative advantage. On these
basis, preventing the functional relationship between uPAR and EGFR
emerges as a reasonable strategy to overcome acquired resistance. To
assess whether uncoupling uPAR-EGFR interaction mediated by the
alpha integrin chain could rescue the response to vemurafenib, resistant
cells were treated with M25, a linear peptide known as integrin antag-
onist (Fig. 5a), in combination with vemurafenib. As shown in Fig. 5b,
M25 and vemurafenib combination reduced the number of colonies of
M6R to a significantly greater extent that M25 and vemurafenib alone.
For comparison, we subjected the M6P to the same treatment and we
observed a similar reduction of the colony number in presence of the
combo.We then investigated the signaling pathway of the resistant
and parental cells and their response to the combination treatment
(Fig. 5c). As previously shown in Fig. 4 E, the enhanced ERK activity
was maintained in M6R cells even following BRAF inhibition, while it
was strongly reduced in theparental cell line. Compared to single agents
alone the combination treatment synergistically reduces pAKT andpERK levels in M6R (Fig. 5c), while in the parental cell line we observed
a synergistic effect of M25 + Vem on ERK phosphorylation alongside a
significant reduction of AKT phosphorylation either after M25 treat-
ment or M25 + Vem. Moreover either M25 or the combo (M25 +
vemurafenib) abrogated mTOR phosphorylation in both cell lines.
Since the dominantmechanism of resistance to vemurafenib inM6R re-
sulted in MEK/ERK signaling reactivation, we evaluated whether these
cells retained the sensitivity toMEK1/2 or ERK1/2 inhibitors. Consistent
with previous findings [35,36], we observed a significant reduction of
ERK1/2 phosphorylation after 24 h treatment with 1 μM of CI-1040 as
MEK1/2 inhibitor while a visible decrease was found in presence of 1
μM SCH772984 as ERK1/2 inhibitor. We also detected a slight increase
of AKT phosphorylation after either MEK1/2 or ERK1/2 inhibition. Nev-
ertheless the combination of either inhibitors with M25 resulted in a
more pronounced decrease of ERK phosphorylation and EGFR protein
levels along with a synergistic reduction of pAKT (Fig. S3a). As previ-
ously shown (Figs. 4E and 5C) no changes were detected in presence
of vemurafenib (Fig. S3a). Morphological modification were observed
either with single MEK1/2 or ERK1/2 inhibitors alone or in combination
with M25 (fig. S3b).Since the effectiveness of M25 wasmore accurately
significant in combination with vemurafenib we then evaluated the po-
tential effect of this combination treatment on an important feature of
cancer cells, such as cell invasion (Fig. 5d and Fig. S4). We performed
cancer cell invasion in a three-dimensionalmatrix, which ismore repre-
sentative of how these cells will actually behave in vivo. In our
Fig. 4. Analysis of the biological andmolecular features of naïve cells and its BRAF-resistant counterpart a. Schematic representation of the induced vemurafenib resistance protocol inM6
cells. b. M6 vem sensitive (M6P) cells and c, M6 vem resistant cells (M6R), were treated for 24 h with DMSO or the indicated doses ofvemurafenib,stained with propidium iodide, and
analyzed for cell cycle progression by flow cytometry. Representative images from one of three independent experiments are shown. The percentage of cells in the different phases of
the cell cycle was calculated by the ModFit program and depicted in each panel. d. M6P and M6R cells (800 cells/ml) were exposed to graded concentrations of vemurafenib for ten
days. Colonies were stained with May Grunwald and the counts reported in the related table. Representative data of three independent experiments is shown (mean ± SD). e.
Immunoblot analysis for AKT, ERK1/2 and mTOR activity in M6R and M6P untreated or treated for 24 h with 2 μM vemurafenib. GAPDH was used as loading control. f. Images of M6P
and M6R spheroids on agar coated plates following treatment with DMSO or μM vemurafenib. Spheroid area is reported on the right. Scale bar = 200 μm.
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vasion as a function of the total area invaded by cells leaving the spher-
oid. As shown in Fig. 5d, M6R cells acquire a more invasive phenotype
compared to parental cells. However, the combination strongly im-
paired invasion compared to the single agents alone. (Fig. 5d). Spher-
oids are supposed to better reflect the in vivo conditions with respect
to drug efficacy.Cell-cell interaction governs the growth, the ability to
maintain the spheroid shape, and affects the drug permeability. In par-
ticular, we observed that the combination treatment dramatically re-
duced the spheroid core area compared to the single agents alone.
Moreover, M25 andM25 plus vemurafenib treatment affected spheroid
shape that indeed started to dismantle and cells became separated from
each other, leading likely to cell death, whereas vemurafenib-treated
spheroid showed a solid round core (Fig. 5e). Immunoprecipitation ex-
periments demonstrated that the effectiveness of M25 atmolecular and
biological levels onM6Rwas due to the ability of this peptide to uncou-
ple uPAR from α5β1 and consequently from EGFR (Fig. 5f). Confocal
immuno-fluorescence analysis of integrin β1/uPAR (Fig. 5g) and
uPAR/EGFR (Fig. S5) confirmed the abrogation of the interaction in pres-
ence of the M25 peptide in M6R as previously observed in M6 wt [37].
All together these results showed that uPAR actively participate to
vemurafenib unresponsiveness to BRAF-I in resistant cells and thus,
uncoupling EGFR/uPAR interaction represents a promising tool to over-
come the acquired resistance.
3.5. Paired high levels of uPAR and EGFR expression correlate in tissue sam-
ples from relapsed patients
Formalin-fixedparaffin-embedded(FFPE) specimens represent a reli-
able clinical source of molecular signatures with great potential ofpredictive features for patient therapy stratification. To evaluate the pos-
sible clinical implications of our in vitro findings, we examined uPAR and
EGFRgeneexpression in tumorbiopsies fromsixpatientswithmetastatic
melanoma (Fig. 6 A) before the BRAF inhibitor Vemurafenib treatment.
The tumors of all six patients were BRAFV600E+ and initially responded
to treatment with Vemurafenib but five of them (patients #2, 3, 4, 5
and 6) relapsed after 3–15months, suggesting that they developed resis-
tance to the BRAF inhibitor and died shortly afterwards. As wewere par-
ticularly interested in our signature's drug response performance, we
chose to adopt the progression as a measure of response/non-response
comparing the uPAR and EGFR levels in relapsed patients with those of
patient #1 who achieved the complete response and is still alive
(Fig. 6B). As reported in fig. 6C we found detectable uPAR levels in 4 re-
lapsed patients: two of them exhibited very high levels (mRNA relative
values ranged from 15 to 53), two of themmoderate levels (1.3 to 2.7).
Nevertheless, EGFR mRNA levels could be quantified in three out of 5
five relapsed patients (relative values fluctuated from 8 to 30). Interest-
ingly, patient #5 with the highest uPAR levels displayed a concomitant
strongest increase of EGFR expression. Although the number of speci-
mens examined was small, due to limited number of patient subjected
to vemurafenibmonotherapy, our findings suggest that uPAR expression
or EGFR could represent a predictive value towards the determination of
patient responsiveness to BRAF inhibitor-based therapies and provide in-
sight into future therapies for the treatment of patients who become re-
fractory to these drugs.
4. Discussion
Acquired resistance to the small molecule BRAF inhibitor,
Vemurafenib (PLX4032), represents the major drawback limiting
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nomas that harbor the V600E BRAF mutation [38–41]. Consequently,
much effort is being focused at identifying the cellular and molecular
mechanisms involved in resistance to BRAF-targeted therapy in these
tumors. The present study is a contribution to these efforts, the results
provide important novel insight into the complexity of the vemurafenib
resistance phenotype in melanoma and advance the basis upon which
such resistance may be overcome clinically. To mimic the clinical situa-
tion in which resistance to vemurafenib frequently occurs after the ini-
tial response to the cure,we induced in vitro vemurafenib resistance in aBRAF-I sensitive human melanoma cell line M6, harboring the V600E
BRAF mutation, by continuous exposure of the cells to vemurafenib.
We considered as an acquired resistancewhenmelanoma cells regained
their original level of proliferation (Fig. 4C and F) and then, we
i) evaluated the biological behavior of naïve cells and their
vemurafenib-resistant counterpart; ii) investigated the molecular sig-
natures, in particular those related to MAPK and PI3K signaling, associ-
ated with the acquisition of vemurafenib resistance. Our study not only
establishes a mechanism of resistance to BRAF inhibition but also pro-
poses a strategy to overcome it.
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characterized uPA receptor (uPAR) acts not only as a promoter of prolif-
eration, invasiveness and angiogenesis in melanoma and other cancer
cell lines [42–45] but also as a factor contributing to the development
of drug resistance. Indeed, we found a remarkable direct association be-
tween uPAR and EGFR co-expression levels and vemurafenib respon-
siveness inV600E BRAF mutated melanoma cells. Noteworthy the
distinctive and simultaneous expression of both uPAR and EGFR protein
levels in three out of seven cell lines was associated with the higher
phosphorylated levels of ERK1/2.
In the first instance we show that lower expression levels of uPAR
and EGFR, displayed by A375 cells, are associated with higher
vemurafenib sensitivity as confirmed by clonogenic assay and short
term cell viability. The link with drug responsiveness was further vali-
dated in a set of clonogenic assays, which proved how uPAR enforced
expression in A375 (Fig. 3d) and M6 (Fig. S2c) cells was able to revert
drug sensitivity to the BRAF inhibitor suggesting that uPAR overexpres-
sion renders melanomas less susceptible to the targeted inhibitor. Quite
the opposite, we demonstrated that uPAR knockdown in A375 cells (Fig.
S2b) and also in M6 (Fig. 3b), which exhibited higher uPAR and EGFR
levels compared to A375 cells, inhibited cell proliferation in combina-
tion with vemurafenib to a greater extent than either treatment alone.
The direct involvement of uPARwas confirmed by the fact that enforced
overexpression did not affect EGFR levels and evenmore by the fact that
its gene silencing paradoxically induces an EGFR slight increase. Taken
together, these data indicate that uPAR plays a direct role in
vemurafenib responsiveness and inhibiting uPAR represents a novel
strategy to enhance melanoma sensitivity to BRAF-I.
At the molecular level we proved that uPAR was able to simulta-
neously affect the two pathways required for BRAFmutatedmelanomas
to proliferate (BRAF/MAPK and PI3K pathways), since inhibition of its
expression by uPAR-specific siRNA causes a reduction of ERK and AKT
activation and restores sensitivity to BRAF-I. This explainswhyuPARde-
pletion is effective as single agent in the colony formation capacity in
the absence of vemurafenib, even though there is clear synergism be-
tween uPAR knockdown and BRAF inhibitor. Moreover we found that
in sensitive cells Vemurafenib itself strongly decreased uPAR protein
levels (Fig. 4e) which reverts to control levels after Vemurafenib ac-
quired resistance and correlates with p- ERK1/2 levels, suggesting reac-
tivation of the BRAF signaling pathway (Figs. 4e and 5c).
As a matter of fact, uPAR is a glycosylphosphatidylinositol-anchored
membrane protein which associates with integrins and RTKs such
as EGFR to form a potent signaling complex [31,37,45].uPAR is
overexpressed in many human malignancies including melanomas
[46–49] and is associated with a worse prognosis especially among
breast cancer and esophageal carcinomas. Our previous findings, along
with the results obtained in other studies, showed that uPAR is anFig. 5. Effect of the combination of Vemurafenib and M25 on the growth, invasion, PI3K and M
interaction. b. Clonogenic assay of M6R and M6P treated with vemurafenib, M25 or the comb
ANOVA test followed by Newman-Keuls post test was used to determine the significance of c
SD; n = 3 experiments; Asterisks indicate significant differences (P b .05.) of the combo versu
or vemurafenib, either administered alone or in combination were harvested for immunoblo
protein phosphorylation levels of AKT, ERK1/2 and mTOR were quantified by densitometry a
ANOVA test followed by Newman-Keuls post test.Error bars indicate mean ± SD; n = 3 expe
DMSO-treated, while number signs indicate significant differences (P b .05) of either M25 or
quantification of M6P and M6R spheroids embedded into the matrigel substrate in presence
invasion cells are depicted in yellow. Scale bar = 200 μm.Measures of invasive areas (invasiv
comparative pictures of M6P and M6R invasive spheroids with the relative invasive area q
presence of either vemurafenib or M25 administered alone or in combination. M6R cells w
Immunoprecipitation of α5β1-integrin. Input: Western blotting of aliquots (30 μg of proteins)
immunoprecipitate (500 μg of proteins) obtained with anti-uPAR R5 antibody; alpha5-beta1
uPAR antibody; EGFR lane: immunoblotting with EGFR antibody: IgG a lysate that was in
Densitometric quantification of the immunoblots normalized to the relative input is reported
Keuls post test.Error bars indicate mean ± SD; Asterisks (p b .05) indicate significant differen
performed three times in triplicate with similar results. g. Representative images of confoca
α5β1 (green) and DAPI (blue). Experiments have been performed three times in triplicate
within each picture as Manders' coefficient (MC). The shown pictures are representative of 20indispensable molecular mediator, in concert with integrin, of tumor
growth, cell invasion and angiogenesis [31,37,45].Since the resistance
to treatment with single inhibitors of the MAPK pathway commonly
emerges, experimental combinatorial therapies have been launched
[50,51]. But early clinical data on BRAF mutant melanoma patients
treated with a combinatorial approach of BRAF and MEK inhibitors
(dabrafenib + trametinib) indicates that, unfortunately, even in that
setting eventually most patients relapse.
Thus, addition of an alternative or third compound prolonging clin-
ical response is highly needed. We set out to demonstrate that uPAR
and EGFR interaction may be successfully leveraged as a novel pharma-
cologic target in M6R. There are a number of previous studies that have
reported the role of the uPAR-integrin-EGFR relationship, leading to de-
fine the so-called “urokinase receptor interactome” [21]. The natural
follow-up of such studies has resulted into attempts to target the
uPAR-integrin-EGFR axis to reduce the “classical” uPAR and EGFR-
dependent cancer signatures (invasion and proliferation) [20,52–61].
Following the beginning of targeted and personalized cancer therapy,
characterized by the use of new cancer-specific molecules (such as
vemurafenib and anti-EGFR antibodies), some studies have addressed
the problem of overcoming pharmacological resistance to such new
therapeutics, upon identification of a role of RTKs in the onset of resis-
tance [62,63]. In view of its integrin-mediated interaction with some
RTKs (and in particular with EGFR), malignancy-linked uPAR overex-
pression has become a natural candidate in resistance-addressed stud-
ies [64,65]. In particular, Tyrosine kinase inhibitor Gefitinib (IRESSA,
ZD 1839), commonly used in mono-therapy for the treatment of non
small cell lung cancer (NSCLC) harboring an activating mutation of
EGFR-tyrosine kinase, significantly reduces EGFR and ERK activation.
CombininguPARdown-regulationwith IRESSA-dependent EGFR inhibi-
tion, showed a synergistic anti-tumor effect in malignant cells of head
and neck cancers and in a series of immortalized cancer cell lines
[66,67].
In this study we proved the efficacy in vitro of M25, a linear peptide
known as integrin antagonist in combinationwith vemurafenib in over-
coming BRAF-I acquired resistance. We found that preventing by M25
the integrin-dependent interaction between uPAR and EGFR restores
the vemurafenib sensitivity in acquired BRAF inhibitor resistant
cells by affecting the BRAF/MAPK and PI3K pathways: blocking
integrin-mediated uPAR-TKRs interaction, while inhibiting the PI3K
pathaway, reactivates the BRAF/MAPK pathway, hence refueling the
vemurafenib-sensitive substrates and hindering the PI3K escape signal-
ing pathway. We believe that its potency in the inhibition of 2D and 3D
cell proliferation as well as in cell invasion has to be attributed to its in-
terference with these two complementary pathways. These results pro-
vide a rationale for clinically exploring the inhibition of EGFR/uPAR
interaction to overcome resistance in uPAR-high, BRAF-mutantAPK signaling pathways of M6R. a. Schematic representation of integrin, EGFR and uPAR
o (vemurafenib + M25) for 10 days. Colonies were stained, and then counted. One-way
ombination treatments versus control and single treatments. Error bars indicate mean ±
s untreated, vemurafenib or M25 treated cells.c.M6R and M6P treated for 24 h with M25
tting with the indicated antibodies. GAPDH was included as a loading control. Relative
nd reported as values normalized to the GAPDH. Significance was assessed by one-way
riments; Asterisks indicate significant differences (P b .05.) of the combo treatment from
Vemurafenib alone from DMSO-treated cells. d. Representative images and invasive area
of either vemurafenib or M25 administered alone or in combination. Cell sprouting and
e area = total area-spheroid area) are reported in graphs on the right panel. On the left,
uantification. e. Representative images of spheroids on agar-coated plates of M6R in
ere pre-incubated with Vemurafenib, M25 or the combo for 24 h. Scale bar = 1 mm. f.
of cell lysates before immunoprecipitation, used as a reference loading control. IP uPAR:
lane: immunoblotting with anti-α5β1 antibody; uPAR lane: immunoblotting with anti-
cubated with non-specific IgG instead of the antibody and used as negative control.
on the right. Significance was assessed by one-way ANOVA test followed by Newman-
ces of either M25 or the combo treatment from DMSO-treated. Experiments have been
l microscopy of companion M6R treated cultures stained with specific anti-uPAR (red),
with analogous results. The co-localization score is quantified by image J andreported
different pictures for each experimental condition. Scale bar = 20 μm.
Fig. 6. uPAR and EGFR expression levels on tumor biopsies of metastatic melanoma patients before vemurafenib treatment: predictive values to BRAF-I responsiveness? A, Biological and
clinical data of the six metastatic melanoma patients treated with vemurafenib as monotherapy. B, Level of uPAR and EGFR expression on isolated micrometastatic cells in 6 patients.
Relative EGFR and uPAR expression levels compared to mRNA 18S and GAPDH on formalin-fixed paraffin embedded (FFPE) melanoma tissue sections from BRAF(V600E) mutant
melanoma patients. C, Scatter plots depicteddirect correlation between uPARand EGFR in relapsedpatients Experiments have been performed three times in triplicatewith similar results.
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hibition of BRAFV600E suppresses the recruitment of tumor-promoting
cell subsets such as Myeloid Derived Suppressor Cells and regulatory T
cells in tumor microenvironments and, on the contrary, sensitizes the
immune system to target tumors by inducing an upregulation of the ex-
pression of melanoma/melanocyte differentiation antigens MART-1,
gp100 and tyrosinase [68,57]. Thus, restoring vemurafenib responsive-
ness in resistant cells by targeting uPAR/EGFR interaction may pave
the way to enhance antitumor immunity and, in combination with im-
munotherapy, may lead to more potent, durable and better individual-
ized treatment in patients with advanced melanoma.
With the aim of pursuing our initial findings on the role of uPAR in
mediating resistance to ERK inhibition,we tried to corroborate these re-
sults in the context of relapsing melanoma patients. From a cohort of 6
patients, we found uPAR to be upregulated in four patients relapsed
with resistant melanoma. In comparison, EGFR gain was found in
three patients. Interestingly one patient in this cohort displayed simul-
taneous expression of both uPARand EGFR. Since almost all the relapsed
patients displayed significant levels of uPAR these data suggested that
uPAR may be a useful biomarker to identify patients with BRAF-
mutant melanoma who will or will not respond to BRAF-I.
In conclusion, we showed that high levels of uPAR lower the sensi-
tivity to vemurafenib in BRAF mutant cells while uPAR loss of function
increases their susceptibility to vemurafenib and restores responsive-
ness in BRAF-I-acquired resistant cells. Understanding the mechanisms
of interaction between uPAR and different tyrosine kinase receptors
(RTK) offers the potential to reveal new opportunities for overcoming
drug resistance and to design drug combinations that will lead to
more potent, durable individualized treatment.
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